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Abstract 
 
The importance of heart rate in the pathophysiology of heart failure with reduced 
LVEF has recently attracted attention. In particular, the findings of the Systolic Heart 
failure treatment with the If inhibitor ivabradine Trial (SHIFT), have put special 
emphasis on heart rate reduction with ivabradine for improvement in clinical 
outcomes. Of course there is a much older drug that reduces heart rate i.e. digoxin. In 
this short commentary we retrospectively analyse the Digitalis Investigation Group 
(DIG) Trial looking at the primary composite endpoint used in SHIFT (i.e. 
cardiovascular death or hospital admission for worsening heart failure) and compare 
the effect of digoxin on this endpoint with that of ivabradine. A remarkably similar 
risk reduction in the composite outcome and in its components appears evident 
amongst patients receiving the active treatment in both studies (although ivabradine 
was added to a beta-blocker whereas digoxin was not). This raises the question of 
whether the Cardiological community dismissed digoxin too readily and if we should 
reappraise its potential role in the treatment of heart failure.  
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The key characteristics of the patients enrolled in the Systolic Heart failure treatment 
with the If inhibitor Ivabradine Trial (SHIFT) and the Digitalis Investigation Group 
trial (DIG) trials are shown in Table 1. The remarkable similarity between the results 
of these 2 trials  (Table 2) is a reminder that, in addition to beta-blockers and 
ivabradine, there is another treatment for heart failure which reduces heart rate i.e. 
digoxin.1,2 
Because it did not reduce mortality and perhaps because it was not promoted, digoxin 
has not been seen as a useful treatment for patients with systolic heart failure in sinus 
rhythm over recent years.3   Contemporaneous trials showing large benefits of 
spironolactone in patients with severe heart failure and similarly impressive benefits 
of beta-blockers across the whole spectrum of symptom severity eclipsed the findings 
of DIG. 4,5-7 
 
Endpoints in DIG and SHIFT  
DIG was also performed at a time when all-cause mortality was perceived to be the 
most appropriate end-point for trials in systolic heart failure.  More recently the 
importance of morbidity, principally heart failure hospitalization, has been recognized 
and it is also now accepted that heart failure interventions are unlikely to reduce non-
cardiovascular death.8  Consequently, the composite morbidity-mortality outcome of 
cardiovascular death or hospitalization for heart failure has become the most 
commonly used endpoint in recent heart failure trials, including SHIFT.2,9,10  Re-
analysis of DIG shows that digoxin led to a highly significant 15 (9-21)% relative risk 
reduction in this composite outcome as compared with an 18 (10-25)% relative risk 
reduction in SHIFT, both p<0.001 (Figure 1 and Table 2).  In both trials the primary 
effect was on heart failure hospitalization without any significant effect on 
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cardiovascular death. Heart failure hospitalization was reduced by 26 (17-34) % with 
ivabradine and by 28 (21-34) % with digoxin (both p<0.001).  Further inspection of 
the two trials shows very similar effects of digoxin on the other outcomes reported by 
the SHIFT investigators. Notably, both drugs reduced the proportion of patients 
admitted to hospital for any reason (Table 2). 
 
Ivabradine and heart rate reduction 
An entry criterion for SHIFT was a heart rate ≥ 70 beats per minute.2  As a 
consequence, the mean baseline heart rate was 80 beats per minute.  Compared with 
placebo, ivabradine reduced heart rate by 11 beats per minute at 28 days and 9 beats 
per minute at 1 year, a greater reduction in heart rate than achieved with digoxin (see 
below).  An earlier trial, morBidity-mortality EvAlUaTion of the If inhibitor 
ivabradine in patients with coronary disease and left-ventricULar dysfunction 
(BEAUTIFUL), required patients to have a heart rate entry of at least 60 beats per 
minute.11  The mean baseline heart rate in BEAUTIFUL was 72 beats per minute and 
the placebo-corrected reduction in heart rate was 7 beats per minute at 6 months and 6 
beats per minute at 12 months.  This latter finding is consistent with the observation 
that the heart rate reduction with ivabradine is greater in patients with a higher starting 
heart rate.2,12  In both trials, the reduction in heart rate was achieved despite the use of 
background beta-blocker therapy (although not always in a recommended dose13).  
 
Digoxin and heart rate reduction in sinus rhythm 
The baseline heart rate in DIG was 78 beats per minute. The use of beta-blockers was 
not recorded but was likely to have been very infrequent.  Although change in heart 
rate was not reported in DIG, prior studies reported the effect of digoxin in patients 
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with heart failure in sinus rhythm.  The largest study to do so was the Randomized 
Assessment of Digoxin on Inhibitors of the Angiotensin Converting Enzyme trial 
(RADIANCE), although this was a trial of digoxin withdrawal.14  Compared with 
continuation of digoxin, withdrawal of digoxin in RADIANCE led to a significant 
increase in heart rate of 7 beats per minute over 3 months from a baseline of 77 per 
minute. Two smaller placebo-controlled cross-over studies showed significant 
reductions in heart rate of 5 to 6 beats per minute.15,16   
The Dutch Ibopamine Multicenter Trial (DIMT) investigators carried out ambulatory 
ECG monitoring in a subset of 50 patients receiving no background heart failure 
therapy.17  These patients were randomized to placebo, ibopamine or digoxin.  Mean 
heart rate over 24 hours did not change from baseline in the placebo or ibopamine 
group but was reduced from 78 ± 7 to 74 ± 8 beats per minute in the digoxin group 
(p=0.005). 
Digoxin is thought to reduce heart rate mainly by enhancing activity of the 
parasympathetic nervous system although it probably also inhibits the sympathetic 
nervous system as it lowers plasma norepinephrine levels.18-21  The vagal actions of 
digoxin also enhance heart-rate variability, an effect that is obtained even with low 
doses.22-24  In contrast to ivabradine, the addition of digoxin to a beta-blocker has not 
been studied in patients with systolic heart failure in sinus rhythm.  As some of the 
heart rate reducing action of digoxin is due to an anti-sympathetic effect, concomitant 
beta-blockade may attenuate the bradycardic response to digoxin.  However it is 
unlikely that beta-blocker treatment will eliminate the heart rate lowering action of 
digoxin which is probably mainly vagally driven.19 Certainly, the combination of 
digoxin and a beta-blocker gives greater heart rate reduction than either drug alone in 
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patients with atrial fibrillation, which is a frequent co-morbidity in patients with heart 
failure (and in which ivabradine is ineffective).25,26  
 
Left ventricular ejection fraction (LVEF) 
As ivabradine’s only known effect is to reduce heart rate, it was surprising that its use 
in SHIFT led to a placebo-corrected increase in LVEF of 2.7% (p<0.001).27  The 
placebo-corrected change in BEAUTIFUL (in which the reduction in heart rate was 
less) was smaller 1.6% (p=0.009).28  Two of the larger controlled trials with digoxin 
showed a placebo-corrected change in LVEF of 3.5% over 6 months (p<0.001) and 
3.7% over 3 months (p<0.01), respectively.29,30  Although it has long been assumed 
that the increase in LVEF with digoxin is due an inotropic action of the drug, the 
findings of SHIFT raise the possibility that some of this effect of digoxin may be 
related to heart rate reduction (although the increase in LVEF with digoxin was 
somewhat greater than in SHIFT despite smaller reductions in heart rate). 
 
Perspective 
The recent finding that lowering heart rate with ivabradine reduces the risk of 
hospitalization for worsening heart failure should make us revisit the role of digoxin 
in the management of heart failure. Although probably not as potently bradycardic as 
ivabradine, digoxin also improves heart rate variability and seems to increase LVEF 
to a greater degree. The benefit of digoxin was demonstrated across the full range of 
heart rates in DIG, although patients in DIG were not treated with a beta-blocker. 
Conversely, in SHIFT, the benefit of ivabradine was shown only in patients with a 
persistently high heart rate, although most patients in that trial were on a beta-blocker.  
Indeed there was a significant interaction between baseline heart rate and the effect of 
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ivabradine in SHIFT, whereby there was a greater benefit of treatment in patients with 
a heart rate of ≥77 beats per minute.2   Interestingly, a recent study has shown patients 
with a persistently high heart rate constitute a small minority of adequately beta-
blocked patients.31  Digoxin is, of course, of value in patients with atrial fibrillation 
whereas ivabradine does not work in these patients. On the other hand, the toxicity of 
digoxin is well recognized and it also has interactions with many other drugs. 
Combination with a beta-blocker has the potential to cause atrioventricular block in 
particular, although more than half of patients in the pivotal beta-blocker trials were 
receiving background digoxin therapy and this problem was reported infrequently.5-7 
Perhaps the findings of SHIFT, together with our retrospective hypothesis-generating 
analysis of DIG, should make us concerned that we dismissed digoxin too readily and 
that we should reconsider whether this inexpensive and generally well tolerated and 
safe agent still has a role to play as a treatment for heart failure? It is worth reflecting 
that in DIG there were 8 fewer patients admitted and 18 fewer admissions per 100 
patients treated with digoxin compared with placebo. In other words, treatment of 13 
patients for 3 years prevented 1 patient being admitted at least once with worsening 
heart failure i.e. the number needed to treat (NNT) for 3 years was only 13.  For 
patients in sinus rhythm, the treatment algorithms in current guidelines recommend 
digoxin almost as a “last resort” in patients who remain significantly symptomatic 
despite everything else – maybe we should reconsider this?3
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FIGURE LEGEND. 
 
Figure 1.   Kaplan-Meier cumulative event curves for the composite outcome of 
cardiovascular death or heart failure hospitalization in the Digitalis 
Investigation Group trial (DIG) [A] and the Systolic Heart failure 
treatment with the If inhibitor Ivabradine Trial (SHIFT) [B*]. 
* Adapted from Lancet 2010; 376: 875-85. 
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Table 1. Baseline characteristics of the patients enrolled in the Digitalis Investigation 
Group trial (DIG) and in the Systolic Heart failure treatment with the If 
inhibitor Ivabradine Trial (SHIFT). 
 
 SHIFT 
n=6505 
DIG 
n=6800 
Age (years) 60 64 
Sex (male) 76% 78% 
Ethnic origin 
  White 
  Nonwhite 
 
89% 
11% 
 
85% 
15% 
BMI 28 27 
Heart rate 80 79 
SBP 122 126 
LVEF 29% 28% 
eGFR 75 64 
NYHA 
  Class I 
  Class II 
  Class III 
  Class IV 
 
- 
49% 
49% 
2% 
 
13% 
54% 
31% 
2% 
Primary cause of HF 
  Ischaemic 
  Non-ischaemic 
 
68% 
32% 
 
71% 
29% 
Prior myocardial infarction 56% 65% 
Hypertension 66% 45% 
Diabetes 30% 28% 
Beta-blocker 89% N/A 
Ace-inhibitor 79% 94% 
ARB 14% 0 
Diuretic 83% 82% 
Antialdosterone agents 60% N/A* 
Cardiac glycosides 22% N/A 
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ICD 3% 0 
CRT 1% 0 
 
 
* Potassium sparing diuretic = 8% 
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Table 2: Clinical outcomes in the Digitalis Investigation Group trial (DIG) and the Systolic Heart failure treatment with the If inhibitor 
Ivabradine Trial (SHIFT). 
 SHIFT DIG 
Outcome Ivabradine 
(n=3241) 
n (%) 
Placebo 
(n=3264) 
n (%) 
HR 
(95% CI) 
 
P value Digoxin 
(n=3397) 
n (%) 
Placebo 
(n=3403) 
n (%) 
HR 
(95% CI) 
 
P value 
Primary composite outcome in SHIFT 
Cardiovascular death or heart failure 
hospitalization 
 
 
793 (24) 
 
937 (29) 
 
0.82 (0.75,0.90) 
 
<0.001 
 
1501 (44) 
 
1653 (49) 
 
0.85 (0.79,0.91) 
 
<0.001 
Hospitalization 
Heart failure hospitalization 
 
514 (16) 
 
672 (21) 
  
0.74 (0.66,0.83) 
 
<0.001 
 
910 (27) 
 
1180 (35) 
 
0.72 (0.66,0.79) 
 
<0.001 
Cardiovascular hospitalization 977 (30) 1122 (34) 0.85 (0.78,0.92) <0.001 1694 (50) 1850 (54) 0.87 (0.81,0.93) <0.001 
All-cause hospitalization 1231 (38) 1356 (42) 0.89 (0.82,0.96) <0.01 2184 (64) 2282 (67) 0.92 (0.87,0.98) <0.01 
 
Deaths 
Heart failure death 
 
113 (3) 
 
151 (5) 
 
0.74 (0.58,0.94) 
 
0.01 
 
394 (12) 
 
449 (13) 
 
0.88 (0.77,1.01) 
 
0.06 
Cardiovascular death 449 (14) 491 (15) 0.91 (0.80,1.03) 0.13 1016 (30) 1004 (30) 1.01 (0.93,1.10) 0.78 
All-cause death 503 (16) 552 (17) 0.90 (0.80,1.02) 0.09 1181 (35) 1194 (35) 0.99 (0.91,1.07) 0.80 
 
HR = hazard ratio CI = confidence interval 
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Figure 1:  Kaplan-Meier cumulative event curves for the composite outcome of cardiovascular death or heart failure hospitalization in the 
Digitalis Investigation Group trial (DIG) [A] and the Systolic Heart failure treatment with the If inhibitor Ivabradine Trial (SHIFT) 
[B*]. * Adapted from Lancet 2010; 376: 875-85. 
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